Loading search results
ATMAII
Sponsor study identifier
observational
365
1 country
1
Study Start
December 2014
Actual (reported)Primary Completion
May 2020
Actual (reported)Study Completion
December 2021
Actual (reported)Food allergy is a common chronic condition in childhood. Recent studies have suggested that the natural history of food allergy has changed during the last two decades, with an increased prevalence, severity of clinical manifestations, and risk of persistence into later ages. The increased food allergy prevalence in children has an important economic impact, with significant direct costs for the healthcare system and even larger costs for the families of food-allergic patients. In addition, children with food allergies are at increased risk to develop other allergic manifestations later in life. According to a recent study, children with a food allergy are 2 to 4 times more likely to develop other atopic manifestations such as asthma (4.0 times), atopic eczema (2.4 times), and respiratory allergies (3.6 times), compared to children without a food allergy. Cow's milk allergy is among the most common food allergy in early childhood, with an estimated prevalence of 2% to 3%. It has been previously showed that in children with cow milk allergy, an extensively hydrolysed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG induced higher tolerance rates compared to extensively hydrolysed casein formula without Lactobacillus rhamnosus GG and other formulas. These findings were consistent with those of a 1-year follow-up study performed in the US that showed better outcomes using an extensively hydrolysed casein formula+Lactobacillus rhamnosus GG vs. an extensively hydrolysed casein formula or amino acid-based formula for the first-line dietary management of cow milk allergy. In addition it has been recently demonstrated that extensively hydrolysed casein formula + Lactobacillus rhamnosus GG reduces the incidence of other atopic manifestations and hastens the development of oral tolerance in children with IgE-mediated cow milk allergy. The present randomized controlled trial (RCT) was designed to test whether different dietary interventions could influence the occurrence of other atopic manifestations in children with IgE-mediated cow milk allergy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2021
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2014
Actual (reported)February 21, 2019
Actual (reported)March 4, 2019
Actual (reported)May 2020
Actual (reported)December 2021
Actual (reported)Rate of subjects with occurrence of other of allergic manifestations
To evaluate the effect of different dietary strategies on the occurrence of eczema, urticaria, asthma and rhinoconjunctivitis in children with IgE-mediated cow milk allergy
3 years
Rate of subjects with tolerance acquisition to cow's milk
3 years
Change in metagenomics and metabolomics
3 years
subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet
subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet
subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet
subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet
hypoallergenic formulas used for cow milk allergy treatment
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Children who were consecutively observed at a FP office because the recent occurrence of signs and symptoms possibly related to IgE-mediated CMA were sent to our tertiary centre for paediatric allergy for possible inclusion in the study. Only subjects who met the inclusion criteria will be invited to participate to the study.Written informed consent will be obtained from the parents of each subject. Anamnestic, demographic, anthropometric and clinical data, as well as information on socio-demographic factors, family and living conditions, parental history of allergic diseases, maternal smoking during pregnancy, environmental tobacco smoke exposure, number of siblings, and pet ownership were obtained from the parents and recorded in a clinical database. For children with sure diagnosis of IgE-mediated CMA during a 3-year follow-up,3 visits every 12 months will be performed. Stool samples for metagenomics and metabolomics and blood sample for epigenetics studies will be collected.
University of Naples Federico II
Naples, 80131, Italy
365 participants (actual enrollment reported by the registry).
First Submitted
February 21, 2019
First Posted
March 4, 2019
Study Start
December 2014
Actual (reported)Epigenetic modifications in cytokines genes
3 years
Epigenetic modifications in cytokines genes
3 years
Rate of subjects with occurrence of other of allergic manifestations
after 4 to 6 years follow-up
subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet
Contact the study team to confirm eligibility.
Primary Completion
May 2020
Actual (reported)Study Completion
December 2021
Actual (reported)Last Updated
June 26, 2024
Record last verified: 2024-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: